Literature DB >> 11966456

Converting a peptide into a drug: strategies to improve stability and bioavailability.

Celine Adessi1, Claudio Soto.   

Abstract

The discovery of peptide hormones, growth factors and neuropeptides implicated in vital biological functions of our organism has increased interest in therapeutic use of short peptides. However, the development of peptides as clinically useful drugs is greatly limited by their poor metabolic stability and low bioavailability, which is due in part to their inability to readily cross membrane barriers such as the intestinal and blood-brain barriers. The aim of peptide medicinal chemistry is, therefore, to develop strategies to overcome these problems. Recent progress in chemical synthesis and design have resulted in several strategies for producing modified peptides and mimetics with lower susceptibility to proteolysis and improved bioavailability, which has increased the probability of obtaining useful drugs structurally related to parent peptides. This review describes different experimental approaches to transforming a peptide into a potential drug and provides examples of the usefulness of these strategies.

Mesh:

Substances:

Year:  2002        PMID: 11966456     DOI: 10.2174/0929867024606731

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  115 in total

1.  NCAD, a database integrating the intrinsic conformational preferences of non-coded amino acids.

Authors:  Guillem Revilla-López; Juan Torras; David Curcó; Jordi Casanovas; M Isabel Calaza; David Zanuy; Ana I Jiménez; Carlos Cativiela; Ruth Nussinov; Piotr Grodzinski; Carlos Alemán
Journal:  J Phys Chem B       Date:  2010-06-03       Impact factor: 2.991

2.  Biosynthesis and antimicrobial evaluation of backbone-cyclized α-defensins.

Authors:  Angie E Garcia; Kenneth P Tai; Shadakshara S Puttamadappa; Alexander Shekhtman; Andre J Ouellette; Julio A Camarero
Journal:  Biochemistry       Date:  2011-11-09       Impact factor: 3.162

Review 3.  Anti-inflammatory defense mechanisms of Entamoeba histolytica.

Authors:  Raúl Silva-García; Guadalupe Rico-Rosillo
Journal:  Inflamm Res       Date:  2010-10-12       Impact factor: 4.575

4.  A straightforward route to enantiopure alpha-substituted derivatives of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid.

Authors:  Francisco J Sayago; M Isabel Calaza; Ana I Jiménez; Carlos Cativiela
Journal:  Tetrahedron       Date:  2009-07-01       Impact factor: 2.457

Review 5.  Issues related to targeted delivery of proteins and peptides.

Authors:  Yingjuan Lu; Jun Yang; Emanuela Sega
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

6.  Design of RNA-targeting macrocyclic peptides.

Authors:  Matthew J Walker; Gabriele Varani
Journal:  Methods Enzymol       Date:  2019-06-13       Impact factor: 1.600

7.  Quantitative evaluation of the relative cell permeability of peptoids and peptides.

Authors:  Yong-Uk Kwon; Thomas Kodadek
Journal:  J Am Chem Soc       Date:  2007-02-14       Impact factor: 15.419

8.  Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor To Achieve High Plasma Stability.

Authors:  Erika J Olson; Bernhard C Lechtenberg; Chunxia Zhao; Elena Rubio de la Torre; Ilaria Lamberto; Stefan J Riedl; Philip E Dawson; Elena B Pasquale
Journal:  ACS Med Chem Lett       Date:  2016-06-25       Impact factor: 4.345

9.  Towards the stereoselective synthesis of alpha-methylated (2S,3aS,7aS)-octahydroindole-2-carboxylic acid.

Authors:  Francisco J Sayago; M Isabel Calaza; Ana I Jiménez; Carlos Cativiela
Journal:  Tetrahedron Asymmetry       Date:  2008-12-12

10.  D-amino acid based protein arginine deiminase inhibitors: Synthesis, pharmacokinetics, and in cellulo efficacy.

Authors:  Kevin L Bicker; Lynne Anguish; Alexander A Chumanevich; Michael D Cameron; Xiangli Cui; Erin Witalison; Venkataraman Subramanian; Xuesen Zhang; Alena P Chumanevich; Lorne J Hofseth; Scott A Coonrod; Paul R Thompson
Journal:  ACS Med Chem Lett       Date:  2012-10-26       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.